[1]
|
OncoTherad® is an immunomodulator of biological response that downregulate RANK/RANKL signaling pathway and PD-1/PD-L1 immune checkpoint in non-muscle invasive bladder cancer
Journal of Cancer Research and Clinical Oncology,
2023
DOI:10.1007/s00432-022-04449-5
|
|
|
[2]
|
A novel therapeutic strategy for non-muscle invasive bladder cancer: OncoTherad® immunotherapy associated with platelet-rich plasma
International Immunopharmacology,
2023
DOI:10.1016/j.intimp.2023.110723
|
|
|
[3]
|
A novel therapeutic strategy for non-muscle invasive bladder cancer: OncoTherad® immunotherapy associated with platelet-rich plasma
International Immunopharmacology,
2023
DOI:10.1016/j.intimp.2023.110723
|
|
|
[4]
|
OncoTherad® (MRB-CFI-1) nano-immunotherapy reduced tumoral progression in non-muscle invasive bladder cancer through activation of Toll-like signaling pathway
Tissue and Cell,
2022
DOI:10.1016/j.tice.2022.101762
|
|
|
[5]
|
OncoTherad® is an immunomodulator of biological response that downregulate RANK/RANKL signaling pathway and PD-1/PD-L1 immune checkpoint in non-muscle invasive bladder cancer
Journal of Cancer Research and Clinical Oncology,
2022
DOI:10.1007/s00432-022-04449-5
|
|
|
[6]
|
OncoTherad® (MRB-CFI-1) nano-immunotherapy reduced tumoral progression in non-muscle invasive bladder cancer through activation of Toll-like signaling pathway
Tissue and Cell,
2022
DOI:10.1016/j.tice.2022.101762
|
|
|
[7]
|
Hybrid graphene oxide as carrier of doxorubicin: cytotoxicity and preliminary in vivo assays against bladder cancer
Advances in Natural Sciences: Nanoscience and Nanotechnology,
2020
DOI:10.1088/2043-6254/ab9194
|
|
|
[8]
|
OncoTherad: A New Nanobiological Response Modifier, its Toxicological and Anticancer Activities
Journal of Physics: Conference Series,
2019
DOI:10.1088/1742-6596/1323/1/012018
|
|
|
[9]
|
Effects of intravesical therapy with platelet-rich plasma (PRP) and Bacillus Calmette-Guérin (BCG) in non-muscle invasive bladder cancer
Tissue and Cell,
2018
DOI:10.1016/j.tice.2018.03.011
|
|
|
[10]
|
Increased toll-like receptors and p53 levels regulate apoptosis and angiogenesis in non-muscle invasive bladder cancer: mechanism of action of P-MAPA biological response modifier
BMC Cancer,
2016
DOI:10.1186/s12885-016-2474-z
|
|
|